Laura Amaya

Laura Amaya

Auto-generated profile, based on publicly available information

Laura Amaya

Center for Personal Dynamic Regulomes, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Molecular Cell
Verified
Journal Article
Closed access
YCY. Grace Chen
Y. Grace Chen
RCRobert Chen
Robert Chen
SASadeem Ahmad
Sadeem Ahmad
RVRohit Verma
Rohit Verma
SKSudhir Pai Kasturi
Sudhir Pai Kasturi
HCHoward Y. Chang
Howard Y. Chang

18 July 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
RCRobert Chen
Robert Chen
SWSean K. Wang
Sean K. Wang
JBJulia A. Belk
Julia A. Belk
LALaura Amaya
Laura Amaya
ZLZhijian Li
Zhijian Li
HCHoward Y. Chang
Howard Y. Chang
Circular RNAs (circRNAs) are stable and prevalent RNAs in eukaryotic cells that arise from back-splicing. Synthetic circRNAs and some endogenous circRNAs can encode proteins, raising the promise of circRNA as a platform for gene expression. In this study, we developed a systematic approach for rapid assembly and testing of features that affect protein production from synthetic circRNAs. To maximize circRNA translation, we optimized five elements: vector topology, 5′ and 3′ untranslated regions, internal ribosome entry sites and synthetic aptamers recruiting translation initiation machinery. Together, these design principles improve circRNA protein yields by several hundred-fold, provide increased translation over messenger RNA in vitro, provide more durable translation in vivo and are generalizable across multiple transgenes.

1 March 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
FBFederica Barzaghi
Federica Barzaghi
LHLaura Cristina Amaya Hernandez
Laura Cristina Amaya Hernandez
BNBenedicte Neven
Benedicte Neven
SRSilvia Ricci
Silvia Ricci
ZKZeynep Yesim Kucuk
Zeynep Yesim Kucuk
RBRosa Bacchetta
Rosa Bacchetta
Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. This analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors. Clinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed. We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS. Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.

8 May 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LALaura Amaya
Laura Amaya
LGLilit Grigoryan
Lilit Grigoryan
ZLZhijian Li
Zhijian Li
ALAudrey Lee
Audrey Lee
PWPaul A. Wender
Paul A. Wender
HCHoward Y. Chang
Howard Y. Chang
Circular RNAs (circRNAs) are a class of RNAs commonly found across eukaryotes and viruses, characterized by their resistance to exonuclease-mediated degradation. Their superior stability compared to linear RNAs, combined with previous work showing that engineered circRNAs serve as efficient protein translation templates, make circRNA a promising candidate for RNA medicine. Here, we systematically examine the adjuvant activity, route of administration, and antigen-specific immunity of circRNA vaccination in mice. Potent circRNA adjuvant activity is associated with RNA uptake and activation of myeloid cells in the draining lymph nodes and transient cytokine release. Immunization of mice with engineered circRNA encoding a protein antigen delivered by a charge-altering releasable transporter induced innate activation of dendritic cells, robust antigen-specific CD8 T cell responses in lymph nodes and tissues, and strong antitumor efficacy as a therapeutic cancer vaccine. These results highlight the potential utility of circRNA vaccines for stimulating potent innate and T cell responses in tissues.

1 January 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MKMatthew A Kunicki
Matthew A Kunicki
LHLaura C. Amaya Hernandez
Laura C. Amaya Hernandez
KDKara L. Davis
Kara L. Davis
RBRosa Bacchetta
Rosa Bacchetta
MRMaria-Grazia Roncarolo
Maria-Grazia Roncarolo
Human CD3+CD4+ Th cells, FOXP3+ T regulatory (Treg) cells, and T regulatory type 1 (Tr1) cells are essential for ensuring peripheral immune response and tolerance, but the diversity of Th, Treg, and Tr1 cell subsets has not been fully characterized. Independent functional characterization of human Th1, Th2, Th17, T follicular helper (Tfh), Treg, and Tr1 cells has helped to define unique surface molecules, transcription factors, and signaling profiles for each subset. However, the adequacy of these markers to recapitulate the whole CD3+CD4+ T cell compartment remains questionable. In this study, we examined CD3+CD4+ T cell populations by single-cell mass cytometry. We characterize the CD3+CD4+ Th, Treg, and Tr1 cell populations simultaneously across 23 memory T cell–associated surface and intracellular molecules. High-dimensional analysis identified several new subsets, in addition to the already defined CD3+CD4+ Th, Treg, and Tr1 cell populations, for a total of 11 Th cell, 4 Treg, and 1 Tr1 cell subsets. Some of these subsets share markers previously thought to be selective for Treg, Th1, Th2, Th17, and Tfh cells, including CD194 (CCR4)+FOXP3+ Treg and CD183 (CXCR3)+T-bet+ Th17 cell subsets. Unsupervised clustering displayed a phenotypic organization of CD3+CD4+ T cells that confirmed their diversity but showed interrelation between the different subsets, including similarity between Th1–Th2–Tfh cell populations and Th17 cells, as well as similarity of Th2 cells with Treg cells. In conclusion, the use of single-cell mass cytometry provides a systems-level characterization of CD3+CD4+ T cells in healthy human blood, which represents an important baseline reference to investigate abnormalities of different subsets in immune-mediated pathologies.

27 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PCPauline P. Chen
Pauline P. Chen
ACAlma-Martina Cepika
Alma-Martina Cepika
RARajni Agarwal
Rajni Agarwal
GSGopin Saini
Gopin Saini
MUMolly J. Uyeda
Molly J. Uyeda
MRMaria Grazia Roncarolo
Maria Grazia Roncarolo
Type 1 regulatory T cells suppress alloreactive immune cells after adoptive transfer in a CTLA-4 and PD-1–mediated manner.